UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

John Carroll Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams ...

UPDATED: Vertex wins a crucial FDA nod for its cystic fibrosis combo, prices at $259,000

Damian Garde Vertex Pharmaceuticals won the FDA's blessing to market a new combination therapy for cystic fibrosis, clearing the way for a drug key to the company's future as ...

UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll Celgene is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront ...

UPDATED: Bristol-Myers dominates–and disappoints–at ASCO immuno-oncology debut

John Carroll Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting ...

UPDATED: GlaxoSmithKline to create new vaccines hub, uprooting R&D groups in Cambridge, Philly

John Carroll GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, ...

UPDATED: Endo aims to lure Salix from Valeant with $175-per-share offer

Carly Helfand Last month, some industry watchers speculated that the low price Valeant agreed to pay for North Carolina's Salix could leave room for other bids. And now, one has ...

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

John Carroll PARIS–Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $ 115 million in the hot American market as it pushes ...

UPDATED: Sanofi drops the ax on 100 R&D staffers in Boston reorganization

John Carroll Just as it was spreading word of a big new development partnership this morning, Sanofi dropped the ax on about 100 employees in a reorganization of its R&D operations. FierceBiotech ...

UPDATED: Intercept shares tank as investigators question OCA’s safety/efficacy for NASH

John Carroll After crunching the data on Intercept's clinical study of OCA for nonalcoholic steatohepatitis, investigators say they tracked some distinct improvements for patients ...

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Emily Wasserman Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market. ...

UPDATED: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies

John Carroll Nymox Pharmaceutical is headed for a bruising opening this morning after putting out word on Sunday that both their late-stage studies of their lead drug flopped as a treatment ...

UPDATED: Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up

John Carroll Novartis is prepping new studies that will test how well three of its oncology drugs–the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia–do ...
Page 3 of 612345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS